Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Jin Hyoung | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Kim, Joo-Hang | - |
dc.contributor.author | Shin, Sang Won | - |
dc.contributor.author | Wang, Xin | - |
dc.contributor.author | Kim, Jong Seok | - |
dc.contributor.author | Orlando, Mauro | - |
dc.contributor.author | Park, Keunchil | - |
dc.date.accessioned | 2021-09-04T01:11:42Z | - |
dc.date.available | 2021-09-04T01:11:42Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89117 | - |
dc.description.abstract | Purpose We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexedcisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). Here, we report on a post hoc subgroup analysis of that study assessing the demographics and disposition of the Korean patient subgroup, and comparing the tolerability of PC/G and gefitinib monotherapy and the tumor response with respect to epidermal growth factor receptor (EGFR) status. Materials and Methods Patients, who were 18 years, chemonalve, Korean, light ex-smokers/never-smokers with advanced NSCLC, were randomly assigned (1:1) to PC/G or gefitinib monotherapy. Treatment-emergent adverse events (TEAEs) were graded, and tumor response was measured as change in lesion sum from baseline at best response. The study was registered with ClinicalTrials.gov, NCT01017874. Results Overall, 111 Korean patients were treated (PC/G, 51; gefitinib, 60). Between-arm characteristics were balanced and similar to those of the overall population. Treatment discontinuations due to adverse events were low (PC/G: 1, 2.0%; gefitinib: 7, 11.7%). Overall, 92 patients (82.9%) reported >= 1 TEAE (PC/G, 44; gefitinib, 48); few patients (PC/G, 16; gefitinib, 7) reported severe TEAEs; the most frequent was neutropenia (PC/G arm) and elevated alanine aminotransferase (gefitinib arm). The lesion sum was decreased by PC/G treatment in most patients, regardless of EGFR mutation status, while gefitinib monotherapy reduced the lesion sum in EGFR-positive patients but had no effect in EGFR-negative patients. Conclusion Our results confirm that both PC/G and gefitinib were well tolerated in Korean patients, regardless of EGFR status; however, patients with EGFR wild-type NSCLC may not benefit from gefitinib monotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.subject | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject | DIAGNOSIS | - |
dc.title | Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Sang Won | - |
dc.identifier.doi | 10.4143/crt.2015.135 | - |
dc.identifier.scopusid | 2-s2.0-84963893732 | - |
dc.identifier.wosid | 000374197200004 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.2, pp.458 - 464 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 458 | - |
dc.citation.endPage | 464 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002099145 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | Non-small-cell lung carcinoma | - |
dc.subject.keywordAuthor | Epidermal growth factor receptor | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Pemetrexed | - |
dc.subject.keywordAuthor | Gefitinib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.